Wed, Sep 3, 2014, 2:10 AM EDT - U.S. Markets open in 7 hrs 20 mins


% | $
Quotes you view appear here for quick access.

Pain Therapeutics Inc. Message Board

  • jmhooker May 20, 2013 2:27 PM Flag

    Embeda Information

    Embeda will not knock Oxycontin or Remoxy out. Embeda sold less than $50 million annually when launched. There have been manufacturing issues like Remoxy and all King did were the same likability studies as Remoxy. The FDA is now requiring more studies like Remoxy to get the abuse resistance labeling. " If Embeda is crushed or chewed, the naltrexone is released and absorbed with the morphine, reversing the morphine's subjective and analgesic effects. The clinical significance of the degree of this reduction has not been established, and there is no evidence that the naltrexone in Embeda reduces the abuse liability of Embeda"

    Sentiment: Hold

4.47+0.25(+5.92%)Sep 2 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.